Insights
Recon takes an analytical look behind select developments in healthcare
Keep up with Recon Strategy Insights
Get an email each time we publish a new article
Search
- By Jason Brauner
The first approval of a gene therapy for congenital disease in the US (Luxturna) inaugurates a new – though long anticipated – era for therapeutics. Along with questions around durability of response …
- By Tory Wolff
During the UnitedHealth quarterly earnings call earlier this month, Larry Renfro, CEO of Optum, offered some additional color on the growth of OptumCare: “Combined with [Davita], OptumCare will be in …
- By Marc Herant
Playing chess against cancer
Tumors are not intelligent, but, because they have escaped mutational control, they constantly probe for mutations that will allow them to escape chemotherapeutic suppress…
- By Miriam Alandydy
- By Tory Wolff
(For background on Pennsylvania market, please take a look at previous note here)
Summary
The UPMC/Highmark rivalry continues to open new fronts in Pennsylvania
Highmark’s response to UPMC is differe…
- By Tory Wolff
(For Louisiana market context, please take a look at previous notes on Ochsner here and here)
Before the holidays, Ochsner signed an LOI to take over the management of ailing University Health located…
- By Marc Herant
Successes in gene therapy for hemophilia B and A
Hemophilia A and B are X-linked genetic diseases which prevents the formation of functional coagulant factors VII and IX respectively and cause a prope…
- By Tory Wolff
OptumHealth and its proposed acquisition target DaVita Medical Group (DMG) have a lot in common:
Ambulatory care portfolios: physician practices, urgent care centers and ambulatory surgical centers (…
- By Tory Wolff
Who will be the first to take integrated health care delivery national?
A few years ago, the best bet might have been an established provider with a nationally compelling brand and a growing affiliate…